HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on BioXcel Therapeutics (NASDAQ:BTAI) but lowered the price target from $10 to $7.
August 08, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on BioXcel Therapeutics but lowered the price target from $10 to $7.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some concerns about future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100